

## Supplementary Material

### **Cs<sub>2</sub>CO<sub>3</sub>-Mediated synthetic strategy for iprobenfos derivatives *via* thiophilic addition of *H*-phosphites on *in situ* generated thioaldehydes**

Rekha Bai,<sup>a</sup> Ke-Chien Liu,<sup>a</sup> Ze-Wei Chen,<sup>a</sup> Asha Gurjar,<sup>d</sup> Satpal Singh Badsara,<sup>d</sup> and Chin-Fa Lee<sup>\*a-c</sup>

<sup>a</sup>*Department of Chemistry, National Chung Hsing University, Taichung, Taiwan 402, R.O.C.*

<sup>b,i</sup>*Center for Advanced Science and Technology (iCAST), National Chung Hsing University, Taichung City 402, Taiwan, R.O.C.*

<sup>c</sup>*Innovation and Development Center of Sustainable Agriculture (IDCSA), National Chung Hsing University, Taichung City 402, Taiwan, R.O.C.*

<sup>d</sup>*MFOS Laboratory, Department of Chemistry, University of Rajasthan, Jaipur, Rajasthan 302004, India*

*E-mail: [cfalee@dragon.nchu.edu.tw](mailto:cfalee@dragon.nchu.edu.tw)*


#### Table of Contents

|  |     |
|--|-----|
| 1. General information   | S2  |
| 2. General procedure for Table 1   | S8  |
| 3. General procedure for Table 2   | S8  |
| 4. References  | S20 |
| 5. <sup>1</sup> H, <sup>13</sup> C, <sup>31</sup> P & <sup>19</sup> F NMR spectra of compounds <b>1</b> & <b>3</b> | S21 |


## 1. General information

Reagents, substrates, and solvents were purchased from commercial suppliers and used without purification. Anhydrous toluene uses calcium hydride to remove water, dry, and distill. Analytical thin-layer chromatography (TLC) was performed using silica gel 60 F<sub>254</sub> (Merck). Chromatography was performed using silica gel 60 (43-63  $\mu\text{m}$ ) (Merck) and Aluminum oxide 90 neutral (MN).  $^1\text{H}$ ,  $^{13}\text{C}$ ,  $^{31}\text{P}$ , and  $^{19}\text{F}$  NMR spectra were using  $\text{CDCl}_3$  on Jeol 400 MHz spectrometers. Tetramethylsilane (TMS) served as an internal standard for  $^1\text{H}$  and  $^{13}\text{C}$  NMR analysis. Chemical shifts in  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra are reported as follows: Chloroform-d (referenced to 7.26 ppm for  $^1\text{H}$  and 77.10 ppm for  $^{13}\text{C}$ ). Coupling constants ( $J$ ) are reported in hertz and peak multiplicities are reported using the following abbreviations: m = multiplet; s = singlet; d = doublet; t = triplet; q = quartet, dd = doublet of doublets, dt = doublet of triplets, dq = doublet of quartets, td = triplet of doublets, tq = triplet of quartets, qd = quartet of doublets, br = broad signal. Low-Resolution Mass Spectrometry (LRMS) experiments were recorded on an Agilent Technologies 5977A with Agilent Technologies 7890B. High-Resolution Mass Spectrometry (HRMS) experiments were recorded on Jeol JMS-HX-110 with EI (Electron Impact) method. All the phosphites 2a & 2b commercially purchased and used without purification and all the thioaldehydes 1a-m were prepared from known literature methods.<sup>1</sup>


### Synthesis of trithiaphosphanes.




In a pre-dried 250 mL flask was added Lawesson's reagent (7 mmol, 2.8 g), Benzaldehydes (10 mmol, 1.061 g) and dry toluene (60 mL) The reaction mixture was vigorously stirred at 80 °C (oil bath) for 12 hours under nitrogen atmosphere. After completion of the reaction, the reaction mixture was filter and solvent was removed. Then the red oil crude was purified by flash aluminium oxide column chromatography (DCM/hexane = 15%) as eluent to afford the pure products **1**.

**2-(4-Methoxyphenyl)-4,6-diphenyl-1,3,5,2-trithiaphosphinane 2-sulfide (1a)**

$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.19 (dd,  $J = 14.6$  &  $9.0$  Hz, 2H), 7.50 (dd,  $J = 8.0$  &  $1.6$  Hz, 4H), 7.40-7.34 (m, 6H), 7.09-7.06 (m, 2H), 6.29 (d,  $J = 9.2$  Hz, 2H), 3.87 (s, 3H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.1, 137.7 (d,  $J = 8.0$  Hz), 133.8 (d,  $J = 14.0$  Hz), 129.2 (d,  $J = 14.0$  Hz), 128.0, 123.1, 122.1, 114.8 (d,  $J = 16.0$  Hz), 58.2, 55.5;  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  72.8. HRMS (EI) calcd for  $\text{C}_{21}\text{H}_{19}\text{OPS}_4$   $[\text{M}]^+$  446.5958 found: 446.0059. M.P.: 78-83 °C

**2-(4-Methoxyphenyl)-4,6-di-*m*-tolyl-1,3,5,2-trithiaphosphinane 2-sulfide (1b)**


$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.19 (dd,  $J = 14.7$  &  $8.9$  Hz, 2H), 7.32-7.23 (m, 6H), 7.15 (d,  $J = 7.0$  Hz, 2H), 7.09-7.06 (m, 2H), 6.25 (d,  $J = 9.2$  Hz, 2H), 3.88 (s, 3H), 2.34 (s, 6H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.1, 139.1, 137.6 (d,  $J = 8.0$  Hz), 133.7 (d,  $J = 13.0$  Hz), 130.1, 128.8 (d,  $J = 43.0$  Hz), 125.1, 123.2, 122.3, 114.6 (d,  $J = 16.0$  Hz), 58.3, 55.6, 21.3;  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  72.7. HRMS (EI) calcd for  $\text{C}_{23}\text{H}_{23}\text{OPS}_4$   $[\text{M}]^+$  474.0369 found: 474.0379. M.P.: 79-83 °C

**2-(4-Methoxyphenyl)-4,6-di-*o*-tolyl-1,3,5,2-trithiaphosphinane 2-sulfide (1c)**

$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.20-8.17 (m, 2H), 7.54-7.52 (m, 2H), 7.24-7.17 (m, 6H), 7.05-7.02 (m, 2H), 6.55 (d,  $J = 9.8$  Hz, 2H), 3.80 (s, 3H), 2.49 (s, 6H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.0 (d,  $J = 3.4$  Hz), 136.1 (d,  $J = 8.0$  Hz), 135.2, 133.5 (d,  $J = 14.0$  Hz), 130.9, 129.1, 128.1, 126.9, 123.1, 122.2, 114.6 (d,  $J = 16.0$  Hz), 55.4 (d,  $J = 19.7$  Hz), 19.2;  $^{31}\text{P}$  NMR


(162 MHz, CDCl<sub>3</sub>):  $\delta$  74.6. HRMS (EI) calcd for C<sub>23</sub>H<sub>23</sub>OPS<sub>4</sub> [M]<sup>+</sup> 474.0369 found: 474.0379. M.P.: 63-68 °C.

### 2-(4-Methoxyphenyl)-4,6-di-*p*-tolyl-1,3,5,2-trithiaphosphinane 2-sulfide (1d)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.19 (dd,  $J$  = 14.6 & 8.9 Hz, 2H), 7.38 (d,  $J$  = 8.1 Hz, 4H), 7.18 (d,  $J$  = 8.0 Hz, 4H), 7.08 (dd,  $J$  = 8.9, 3.3 Hz, 2H), 6.24 (d,  $J$  = 9.2 Hz, 2H), 3.89 (s, 3H), 2.34 (s, 6H); <sup>13</sup>C {H} NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  164.2 (d,  $J$  = 3.4 Hz), 139.4, 134.8 (d,  $J$  = 8.7 Hz), 133.6 (d,  $J$  = 13.5 Hz), 130.1, 129.9, 129.4 (d,  $J$  = 6.0 Hz), 128.5, 127.8 (d,  $J$  = 14.4 Hz), 127.5, 123.3, 122.3, 114.6 (d,  $J$  = 15.0 Hz), 58.1, 55.6, 21.3; <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  72.7. HRMS (EI) calcd for C<sub>23</sub>H<sub>23</sub>OPS<sub>4</sub> [M]<sup>+</sup> 474.0369 found: 474.0379. M.P.: 65-72 °C.

### 4,6-Bis(3-methoxyphenyl)-2-(4-methoxyphenyl)-1,3,5,2 trithia-phosphinane 2-sulfide (1e)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.22-8.16 (m, 2H), 7.29-7.25 (m, 2H), 7.09-7.06 (m, 4H), 7.02-7.00 (m, 2H), 6.90-6.87 (m, 2H), 6.24 (d,  $J$  = 9.1 Hz, 2H), 3.89 (s, 3H), 3.81 (s, 6H); <sup>13</sup>C {H} NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  164.0 (d,  $J$  = 3.0 Hz), 160.0, 138.8 (d,  $J$  = 9.1 Hz), 133.5 (d,  $J$  = 13.1 Hz), 130.2, 122.9, 121.9, 115.3, 114.5 (d,  $J$  = 16.2 Hz), 113.1, 58.3, 55.5, 55.3; <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  72.7. HRMS (EI) calcd for C<sub>23</sub>H<sub>23</sub>O<sub>3</sub>PS<sub>4</sub> [M]<sup>+</sup> 506.0268 found: 506.0271.

### 2,4,6-Tris(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (1f)




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.22-8.15 (m, 2H), 7.44-7.40 (m, 4H), 7.09-7.05 (m, 2H), 6.90-6.86 (m, 5H), 6.20 (d,  $J = 8$  Hz, 2H), 3.88 (s, 3H), 3.79 (s, 6H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.0 (d,  $J = 3.0$ ), 160.2, 133.7 (d,  $J = 13.1$  Hz), 131.9, 129.8 (d,  $J = 10.0$  Hz), 129.3, 128.8, 123.2, 122.1, 114.6, 114.4, 57.8, 55.6, 55.4;  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  72.7. HRMS (EI) calcd for  $\text{C}_{23}\text{H}_{23}\text{O}_3\text{PS}_4$   $[\text{M}]^+$  506.0268 found: 506.0276.

#### 4,6-Bis(4-fluorophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (1g)




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.21-8.15 (m, 2H), 7.50-7.45 (m, 4H), 7.10-7.04 (m, 6H), 6.25 (d,  $J = 9.1$  Hz, 2H), 3.88 (s, 3H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.3, 161.8, 133.7 (d,  $J = 14.0$  Hz), 129.9 (d,  $J = 8.2$  Hz), 122.8, 121.8, 116.3 (d,  $J = 21.7$  Hz), 114.6 (d,  $J = 15.9$  Hz), 57.4, 55.6;  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  72.8.  $^{19}\text{F}$  NMR (376 MHz,  $\text{CDCl}_3$ ):  $\delta$  -110.8. HRMS (EI) calcd for  $\text{C}_{21}\text{H}_{17}\text{F}_2\text{OPS}_4$   $[\text{M}]^+$  481.9868 found: 481.9871. M.P.: 130-135 °C.

#### 4,6-Bis(4-chlorophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (1h)




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.19-8.13 (m, 2H), 7.44-7.24 (m, 8H), 7.10-7.07 (m, 2H), 6.25 (d,  $J = 9.1$  Hz, 2H), 3.88 (s, 3H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.4, 136.0 (d,  $J = 9.2$  Hz), 135.3, 133.6 (d,  $J = 14.0$  Hz), 129.4 (d,  $J = 7.0$  Hz), 122.7, 121.7, 114.7 (d,  $J = 15.9$  Hz), 57.6, 55.7;  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  72.8. HRMS (EI) calcd for  $\text{C}_{21}\text{H}_{17}\text{Cl}_2\text{OPS}_4$   $[\text{M}]^+$  513.9277 found: 513.9282.

#### 4,6-Bis(3-bromophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (1i)




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.21-8.13 (m, 2H), 7.66 (t,  $J = 1.9$  Hz, 2H), 7.48 (dq,  $J = 8.0$  & 1.0 Hz, 2H), 7.43-7.40 (m, 2H), 7.26-7.22 (m, 2H), 7.10-7.06 (m, 2H), 6.23 (d,  $J = 9.1$  Hz, 2H), 3.88 (s, 3H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.4, 139.3 (d,  $J = 8.0$  Hz), 133.6 (d,  $J = 14.0$  Hz), 132.6, 130.6 (d,  $J = 35.2$  Hz), 126.7, 123.1, 122.6, 121.7, 114.7 (d,  $J = 16.4$  Hz), 57.5, 55.7.  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  72.7. HRMS (EI) calcd for  $\text{C}_{21}\text{H}_{17}\text{Br}_2\text{OPS}_4$   $[\text{M}]^+$  601.8267 found: 601.8274. M.P.: 86-90 °C.

#### 4,6-Bis(4-bromophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (1j)




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.19-8.13 (m, 2H), 7.51-7.30 (m, 8H), 7.08-7.05 (m, 2H), 6.23 (d,  $J = 9.2$  Hz, 2H), 3.85 (s, 3H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.2, 136.6 (d,  $J = 9.2$  Hz), 133.7 (d,  $J = 14.0$  Hz), 132.3 (d,  $J = 14.0$  Hz), 123.5, 122.6, 121.6, 114.7 (d,  $J = 16.0$  Hz), 57.7, 55.6;  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  72.6. HRMS (EI) calcd for  $\text{C}_{21}\text{H}_{17}\text{Br}_2\text{OPS}_4$   $[\text{M}]^+$  601.8274 found: 601.8262.


#### 4,6-Bis(4-iodophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (1k)




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.20-8.13 (m, 2H), 7.73-7.70 (m, 4H), 7.26-7.21 (m, 4H), 7.10-7.01 (m, 2H), 6.20 (d,  $J = 9.1$  Hz, 2H), 3.90 (s, 3H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.3, 138.4, 137.1 (d,  $J = 9.0$  Hz), 133.8 (d,  $J = 14.1$  Hz), 130.9, 129.3, 114.8 (d,  $J = 16.0$  Hz), 95.4, 57.7, 55.7;  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  72.7. HRMS (EI) calcd for  $\text{C}_{21}\text{H}_{17}\text{I}_2\text{OPS}_4$   $[\text{M}]^+$  697.7989 found: 697.7981.

**2-(4-Methoxyphenyl)-4,6-di(naphthalen-2-yl)-1,3,5,2-trithiaphosphinane 2-sulfide (1l)**

$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.27-8.21 (m, 2H), 8.02 (d,  $J = 1.5$  Hz, 2H), 7.86 (s, 2H), 7.83-7.79 (m, 6H), 7.60 (dd,  $J = 8.5$  & 1.9 Hz, 2H), 7.51-7.46 (m, 4H), 7.09-7.06 (m, 2H), 6.52 (d,  $J = 9.2$  Hz, 2H), 3.86 (s, 3H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.2, 135.0, 133.8 (d,  $J = 9.2$  Hz), 133.4 (d,  $J = 18.2$  Hz), 129.2, 128.2, 127.8, 127.6, 126.9, 126.7, 125.4, 123.1, 122.1, 114.7 (d,  $J = 15.9$  Hz), 58.6, 55.8;  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  72.9 M.P.: 150-155 °C

**2-(4-Methoxyphenyl)-4,6-di(thiophen-2-yl)-1,3,5,2-trithiaphosphinane 2-sulfide (1m)**

$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.19-8.13 (m, 2H), 7.32-7.29 (m, 2H), 7.25-7.23 (m, 2H), 7.09-6.97 (m, 4H), 6.56 (d,  $J = 12$  Hz, 2H), 3.88 (s, 3H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.3, 139.0 (d,  $J = 11.0$  Hz), 138.7, 133.7 (d,  $J = 14.0$  Hz), 127.3 (d,  $J = 12.0$  Hz), 127.1, 126.9, 126.3, 122.4, 121.4, 114.7 (d,  $J = 16.2$  Hz), 55.7, 53.5;  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  72.5.


**2-(4-Methoxyphenyl)-4,6-bis(4-nitrophenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (1n)**

$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.29-8.24 (m, 5H), 7.72-7.68 (m, 4H), 7.14-7.10 (m, 2H), 6.42 (d,  $J = 8.0$  Hz, 2H), 3.93 (s, 3H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  164.7, 148.3, 143.7 (d,  $J = 8.0$  Hz), 133.7 (d,  $J = 14.0$  Hz), 129.3, 124.7, 124.0, 114.9 (d,  $J = 16.2$  Hz), 57.5, 55.8.  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  72.9.

## 2. General procedure for table 1

In a sealed tube, 2-(4-methoxyphenyl)-4,6-diphenyl-1,3,5,2-trithiaphosphinane 2-sulfide (**1a**) (267.9 mg, 0.6 mmol), base (40 mol %) was added in a glove box, followed by diethyl phosphites **2a** (55.24 mg, 0.4 mmol) and solvent (2 mL) were added, and stir at 80-100 °C for 8-10 hours. After completion of the reaction, the reaction mixture was diluted with ethyl acetate and filtered through a celite pad and concentrated under reduced pressure. The crude product thus obtained was then purified by column chromatography using silica gel (300-400 mesh) (15% ethyl acetate in hexanes) to obtain the pure product of **3a**.

### Representative example of Table 1: *S*-Benzyl *O,O*-diisobutyl phosphorothioate (**3a**)<sup>2</sup>




Yield: 77.66 mg, 65%; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.37-7.24 (m, 5H), 4.16-3.96 (m, 6H), 1.28 (t, *J*=7.2 Hz, 6H); <sup>13</sup>C {H}NMR (100 MHz, CDCl<sub>3</sub>): δ 137.4 (d, *J* = 6.0 Hz), 128.9, 128.6, 127.6, 63.5 (d, *J* = 6.0 Hz), 34.9 (d, *J* = 3.0 Hz), 15.9 (d, *J* = 7.0 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 27.3.

## 3. General procedure for Table 2

In a sealed tube, added **1** (0.6 mmol), cesium carbonate (40 mol %) in a glove box, then dialkyl phosphites **2** (0.4 mmol) and ethyl acetate (2 mL) were added, the reaction mixture was then heated for 10 hours at 80 °C. After completion of the reaction, the reaction mixture was diluted with ethyl acetate and filtered through a celite pad and concentrated under reduced pressure. The crude product thus obtained was purified by column chromatography using silica gel (300-400 mesh) (10-20% ethyl acetate in hexanes) to obtain the pure products **3**.

### *O,O*-Diethyl *S*-(3-methylbenzyl) phosphorothioate (**3b**)<sup>3</sup>




The title compound was prepared following the general procedure for table 2, using 2-(4-methoxyphenyl)-4,6-di-*m*-tolyl-1,3,5,2-trithiaphosphinane 2-sulfide (**1b**) (284.7 mg, 0.6 mmol), diethyl phosphite (**2a**) (55.24 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3b**




(66.92 mg, 61% yield);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.27-7.14 (m, 3H), 7.08 (d,  $J = 7.2$  Hz, 1H), 4.18-3.98 (m, 6H), 2.34 (s, 3H), 1.29 (t,  $J = 7.2$  Hz, 6H);  $^{13}\text{C}$  {H} NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  138.2, 137.3 (d,  $J = 6.0$  Hz), 129.6, 128.6, 128.4, 125.9, 63.5 (d,  $J = 5.0$  Hz), 34.9 (d,  $J = 4.0$  Hz), 21.3, 15.9 (d,  $J = 8.0$  Hz);  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  27.4. HRMS (EI) calcd for  $\text{C}_{12}\text{H}_{19}\text{O}_3\text{PS}$   $[\text{M}]^+$  274.0793 found: 274.0784.

### *O,O*-Diethyl *S*-(2-methylbenzyl) phosphorothioate (**3c**)<sup>3</sup>




The title compound was prepared following the general procedure for table 2, using 2-(4-methoxyphenyl)-4,6-di-*o*-tolyl-1,3,5,2-trithiaphosphinane 2-sulfide (**1c**) (284.7 mg, 0.6 mmol), diethyl phosphite **2a** (55.24 mg, 0.4 mmol),  $\text{Cs}_2\text{CO}_3$  (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography ( $\text{SiO}_2$ , ethyl acetate/hexane) to provide **3c** (65.82 mg, 60% yield);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.31 (d,  $J = 6.8$  Hz, 1H), 7.21-7.13 (m, 3H), 4.18-3.99 (m, 6H), 2.40 (s, 3H), 1.30 (td,  $J = 7.2$  & 0.8 Hz, 6H);  $^{13}\text{C}$  {H} NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  136.6, 135.1 (d,  $J = 6.0$  Hz), 130.6, 130.0, 128.1, 126.2, 63.5 (d,  $J = 6.0$  Hz), 33.1 (d,  $J = 3.0$  Hz), 19.2, 16.0 (d,  $J = 8.0$  Hz);  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  27.4.


### *O,O*-diethyl *S*-(4-methylbenzyl) phosphorothioate (**3d**)<sup>3</sup>




The title compound was prepared following the general procedure for table 2, using 2-(4-methoxyphenyl)-4,6-di-*p*-tolyl-1,3,5,2-trithiaphosphinane 2-sulfide (**1d**) (284.7 mg, 0.6 mmol), diethyl phosphite (**2a**) (55.24 mg, 0.4 mmol),  $\text{Cs}_2\text{CO}_3$  (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography ( $\text{SiO}_2$ , ethyl acetate/hexane) to provide **3d** as a colorless liquid (66.92 mg, 61% yield);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.23 (d,  $J = 8.0$  Hz, 2H), 7.20 (d,  $J = 8.0$  Hz, 2H), 4.73-3.98 (m, 6H), 2.32 (s, 3H), 1.29 (t,  $J = 7.2$  Hz, 6H).  $^{13}\text{C}$  {H} NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  137.2, 134.2 (d,  $J = 6.0$  Hz), 129.2, 128.7, 63.4 (d,  $J = 5.0$  Hz), 34.6 (d,  $J = 4.0$  Hz), 21.0 (s), 15.8 (d,  $J = 7.0$  Hz);  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ )  $\delta$  27.5. HRMS (EI) calcd for  $\text{C}_{12}\text{H}_{19}\text{O}_3\text{PS}$   $[\text{M}]^+$  274.0793 found: 274.0784.

***O,O*-diethyl *S*-(3-methoxybenzyl) phosphorothioate (**3e**)**

The title compound was prepared following the general procedure for table 2, using 4,6-bis(3-methoxyphenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1e**) (304.0 mg, 0.6 mmol), diethyl phosphite **2a** (55.24 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3e** as a colorless liquid (40.66 mg, 35% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.23 (t, *J* = 8.0 Hz, 1H), 6.95-6.90 (m, 2H), 6.80 (dd, *J* = 8.4 & 2.4 Hz, 1H), 4.17-3.98 (m, 6H), 3.80 (s, 3H), 1.29 (t, *J* = 7.2 Hz, 6H); <sup>13</sup>C {H} NMR (100 MHz, CDCl<sub>3</sub>): δ 159.6, 138.9 (d, *J* = 6.0 Hz), 129.6, 121.0, 114.3, 113.2, 63.4 (d, *J* = 6.0 Hz), 55.1, 34.8 (d, *J* = 4.0 Hz), 15.8 (d, *J* = 8.0 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 27.3. HRMS (EI) calcd for C<sub>12</sub>H<sub>19</sub>O<sub>4</sub> PS [M]<sup>+</sup> 290.0742 found: 290.0743.

***O,O*-diethyl *S*-(4-methoxybenzyl) phosphorothioate (**3f**)<sup>4</sup>**


The title compound was prepared following the general procedure for table 2, using 2,4,6-tris(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1f**) (304.0 mg, 0.6 mmol), diethyl phosphite (**2a**) (55.24 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3f** (56.90 mg, 49% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.27 (d, *J* = 8.8 Hz, 2H), 6.84 (d, *J* = 8.8 Hz, 2H), 4.17-3.98 (m, 6H), 3.79 (s, 3H), 1.29 (t, *J* = 7.2 Hz, 6H); <sup>13</sup>C {H} NMR (100 MHz, CDCl<sub>3</sub>): δ 159.0, 130.1, 129.4 (d, *J* = 6.0 Hz), 114.0, 63.4 (d, *J* = 6.0 Hz), 55.3, 34.5 (d, *J* = 4.0 Hz), 15.9 (d, *J* = 8.0 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 27.5.

***O,O*-diethyl *S*-(4-fluorobenzyl) phosphorothioate (**3g**)<sup>5</sup>**

The title compound was prepared following the general procedure for table 2, using 4,6-bis(4-


fluorophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1g**) (289.4 mg, 0.6 mmol), diethyl phosphite **2a** (55.24 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3g** (55.65 mg, 50% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.35-7.31 (m, 2H), 7.03-6.97 (m, 2H), 4.16-3.97 (m, 6H), 1.29 (td, *J* = 7.2 & 0.8 Hz, 6H); <sup>13</sup>C{<sup>1</sup>H}NMR (100 MHz, CDCl<sub>3</sub>): δ 162.2 (d, *J* = 236.0 Hz), 133.4 (dd, *J* = 4.0 & 5.0 Hz), 130.4 (d, *J* = 9.0 Hz), 115.4 (d, *J* = 21.0 Hz), 63.5 (d, *J* = 6.0 Hz), 34.1 (d, *J* = 3.0 Hz), 15.8 (d, *J* = 7.0 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 27.1; <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ -114.5. HRMS (EI) calcd for C<sub>11</sub>H<sub>16</sub>FO<sub>3</sub>PS [M]<sup>+</sup> 278.0542 found: 278.0544.

### ***S*-(4-chlorobenzyl) *O,O*-diethyl phosphorothioate (**3h**)<sup>3</sup>**



The title compound was prepared following the general procedure for table 2, using 4,6-bis(4-chlorophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1h**) (309.2 mg, 0.6 mmol), diethyl phosphite **2a** (55.24 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3h** (35.28 mg, 30% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.32-7.27 (m, 4H), 4.16-3.97 (m, 6H), 1.29 (td, *J* = 3.2 & 0.8 Hz, 6H); <sup>13</sup>C{<sup>1</sup>H}NMR (100 MHz, CDCl<sub>3</sub>): δ 136.2 (d, *J* = 5.0 Hz), 133.5, 130.3, 128.8, 63.6 (d, *J* = 5.0 Hz), 34.2 (d, *J* = 3.9 Hz), 15.9 (d, *J* = 7.0 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 27.0. HRMS (EI) calcd for C<sub>11</sub>H<sub>16</sub>ClO<sub>3</sub>PS [M]<sup>+</sup> 294.0246 found: 294.0238.


### ***O,O*-diethyl *S*-(3-bromobenzyl) phosphorothioate (**3i**)**



The title compound was prepared following the general procedure for table 2, using 4,6-bis(3-bromophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1i**) (362.6 mg, 0.6 mmol), diethyl phosphite (**2a**) (55.24 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3i** (56.98 mg, 42% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.52 (s, 1H), 7.40 (d, *J* = 8.0 Hz, 1H), 7.29 (d, *J* = 8.0 Hz, 1H), 7.19 (t, *J* = 8.0 Hz, 1H), 4.17-3.97 (m, 6H), 1.30 (t, *J* = 0.8 Hz, 6H);


$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  139.9 (d,  $J = 4.0$  Hz), 131.8, 130.6, 130.1, 127.5, 122.4, 63.6 (d,  $J = 6.0$  Hz), 34.2 (d,  $J = 4.0$  Hz), 15.9 (d,  $J = 7.0$  Hz);  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  26.7. HRMS (EI) calcd for  $\text{C}_{11}\text{H}_{16}\text{BrO}_3\text{PS}$   $[\text{M}]^+$  337.9741 found: 337.9739.

### ***O,O*- diethyl *S*-(4-bromobenzyl) phosphorothioate (**3j**)<sup>6</sup>**




The title compound was prepared following the general procedure for table 2, using 4,6-bis(4-bromophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1j**) (362.6 mg, 0.6 mmol), diethyl phosphite (**2a**) (55.24 mg, 0.4 mmol),  $\text{Cs}_2\text{CO}_3$  (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography ( $\text{SiO}_2$ , ethyl acetate/hexane) to provide **3j** (61.05 mg, 45% yield);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.46-7.43 (m, 2H), 7.27-7.22 (m, 2H), 4.16-3.96 (m, 6H), 1.28 (td,  $J = 7.2$  & 0.8 Hz, 6H);  $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  136.6 (d,  $J = 5.0$  Hz), 131.7, 130.6, 121.5, 63.6 (d,  $J = 6.0$  Hz), 34.2 (d,  $J = 4.0$  Hz), 15.9 (d,  $J = 7.0$  Hz);  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  26.9. HRMS (EI) calcd for  $\text{C}_{11}\text{H}_{16}\text{BrO}_3\text{PS}$   $[\text{M}]^+$  337.9741 found: 337.9739.

### ***O,O*- diethyl *S*-(4-iodobenzyl) phosphorothioate (**3k**)**




The title compound was prepared following the general procedure for table 2, using 4,6-bis(4-iodophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1k**) (419.0 mg, 0.6 mmol), diethyl phosphite (**2a**) (55.24 mg, 0.4 mmol),  $\text{Cs}_2\text{CO}_3$  (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography ( $\text{SiO}_2$ , ethyl acetate/hexane) to provide **3k** (77.2 mg, 50% yield);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.64 (d,  $J = 8.4$  Hz, 2H), 7.12 (d,  $J = 8.4$  Hz, 2H), 4.15-3.94 (m, 6H), 1.28 (td,  $J = 7.2$  & 0.8 Hz, 6H);  $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  137.6, 137.2 (d,  $J = 5.0$  Hz), 130.7, 93.0, 63.5 (d,  $J = 6.0$  Hz), 34.2, 15.8 (d,  $J = 8.0$  Hz);  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ )  $\delta$  26.8; HRMS (EI) calcd for  $\text{C}_{11}\text{H}_{16}\text{IO}_3\text{PS}$   $[\text{M}]^+$  385.9602 found: 385.9599.

### ***O,O*-diethyl *S*-(naphthalen-2-ylmethyl) phosphorothioate (**3l**)**




The title compound was prepared following the general procedure for table 2, using 2-(4-methoxyphenyl)-4,6-di(naphthalen-2-yl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1l**) (328.0 mg, 0.6 mmol), diethyl phosphite (**2a**) (55.24 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3l** (74.48 mg, 60% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (d, *J* = 8.4 Hz, 1H), 7.84 (d, *J* = 8.0 Hz, 1H), 7.77 (d, *J* = 8.0 Hz, 1H), 7.57-7.47 (m, 3H), 7.37 (t, *J* = 7.6 Hz, 1H), 4.49 (d, *J* = 12.4 Hz, 2H), 4.16-3.95 (m, 4H), 1.25 (t, *J* = 7.2 Hz, 6H); <sup>13</sup>C{H}NMR (100 MHz, CDCl<sub>3</sub>): δ 133.6, 132.6 (d, *J* = 6.0 Hz), 130.89, 128.8, 128.7, 127.6, 126.3, 125.8, 125.2, 123.4, 63.5 (d, *J* = 6.0 Hz), 32.7 (d, *J* = 3.0 Hz), 15.8 (d, *J* = 7.0 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 27.3. HRMS (EI) calcd for C<sub>15</sub>H<sub>19</sub>O<sub>3</sub>PS [M]<sup>+</sup> 310.0793 found: 310.0789.

### *O,O*-diethyl *S*-(thiophen-2-ylmethyl) phosphorothioate (**3m**)<sup>7</sup>



The title compound was prepared following the general procedure for table 2, using 2-(4-methoxyphenyl)-4,6-di(thiophen-2-yl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1m**) (275.1 mg, 0.6 mmol), diethyl phosphite (**2a**) (55.24 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3m** (44.69 mg, 42% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.23 (dd, *J* = 5.2 & 2.0 Hz, 1H), 7.03 (d, *J* = 3.2 Hz, 1H), 6.93-6.90 (m, 1H), 4.27 (d, *J* = 14.0 Hz, 2H), 4.20-4.01 (m, 4H), 1.31 (t, *J* = 7.2 Hz, 6H); <sup>13</sup>C{H}NMR (100 MHz, CDCl<sub>3</sub>): δ 140.0 (d, *J* = 6.0 Hz), 127.1, 126.9, 125.7, 63.6 (d, *J* = 5.0 Hz), 29.5 (d, *J* = 3.0 Hz), 15.9 (d, *J* = 7.0 Hz); <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 26.7. HRMS (EI) calcd for C<sub>9</sub>H<sub>15</sub>O<sub>3</sub>PS<sub>2</sub> [M]<sup>+</sup> 266.0200 found: 266.0206.


### *S*-benzyl *O,O*-diisobutyl phosphorothioate (**3n**)<sup>5</sup>



The title compound was prepared following the general procedure for table 2, using 2-(4-methoxyphenyl)-4,6-diphenyl-1,3,5,2-trithiaphosphinane 2-sulfide (**1a**) (267.9 mg, 0.6 mmol),


di-isobutyl phosphite (**2b**) (77.68 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3n** (88.58 mg, 70% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.39-7.24 (m, 5H), 4.04 (d, *J* = 14.0 Hz, 2H), 3.84-3.78 (m, 2H), 3.73-3.67 (m, 2H), 1.95-1.85 (m, 2H), 0.92 (d, *J* = 1.2 Hz, 6H), 0.90 (d, *J* = 1.2 Hz, 6H); <sup>13</sup>C {H} NMR (100 MHz, CDCl<sub>3</sub>): δ 137.5 (d, *J* = 5.0 Hz), 128.9, 128.7, 127.6, 73.3 (d, *J* = 7.0 Hz), 34.9 (d, *J* = 3.0 Hz), 28.9 (d, *J* = 8.0 Hz), 18.7; <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 27.4.

### *O,O*-Diisobutyl *S*-(4-methylbenzyl) phosphorothioate (**3o**)<sup>5</sup>



The title compound was prepared following the general procedure for table 2, using 2-(4-methoxyphenyl)-4,6-di-*p*-tolyl-1,3,5,2-trithiaphosphinane 2-sulfide (**1d**) (284.7 mg, 0.6 mmol), di-isobutyl phosphite (**2b**) (77.68 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3o** (72.69 mg, 55% yield); <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29-7.26 (m, 2H), 6.86-6.83 (m, 2H), 4.01 (d, *J* = 13.2 Hz, 2H), 3.84-3.79 (m, 5H), 3.74-3.58 (m, 2H), 1.96-1.85 (m, 2H), 0.93(d, *J* = 1.2 Hz, 6H), 0.91 (d, *J* = 1.2 Hz, 6H); <sup>13</sup>C {H} NMR (100 MHz, CDCl<sub>3</sub>): δ 159.0, 130.1, 129.4 (d, *J* = 6.0 Hz), 114.0, 73.3 (d, *J* = 7.0 Hz), 55.3, 34.4, (d, *J* = 4.0 Hz), 28.9 (d, *J* = 7.0 Hz), 18.7. <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>) δ 27.5. HRMS (EI) calcd for C<sub>16</sub>H<sub>27</sub>O<sub>3</sub> PS [M]<sup>+</sup> 330.1419 found: 330.1422.


### *O,O*-Diisobutyl *S*-(3-methylbenzyl) phosphorothioate (**3p**)



The title compound was prepared following the general procedure for table 2, using 2-(4-methoxyphenyl)-4,6-di-*m*-tolyl-1,3,5,2-trithiaphosphinane 2-sulfide (**1b**) (284.7 mg, 0.6 mmol), di-isobutyl phosphite (**2b**) (77.68 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (53.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3p** (76.65 mg, 58% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.23 (t, *J* = 8.0 Hz, 1H), 6.94 (d, *J* = 7.6 Hz, 1H), 6.91 (t, *J* = 2.0 Hz, 1H), 6.81 (dd, *J* = 8.4 & 2.4 Hz, 1H), 4.02 (d, *J* = 13.6 Hz,


2H), 3.85-3.79 (m, 5H), 3.75-3.69 (m, 2H), 1.96-1.86 (m, 2H), 0.93 (d,  $J = 1.2$  Hz, 6H), 0.91 (d,  $J = 1.2$  Hz, 6H).  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  159.7, 139.0 (d,  $J = 5.0$  Hz), 129.7, 121.2, 114.4, 113.3, 73.4 (d,  $J = 6.0$  Hz), 55.3, 34.9, (d,  $J = 4.0$  Hz), 29.0 (d,  $J = 7.0$  Hz), 18.7.  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ )  $\delta$  27.4. HRMS (EI) calcd for  $\text{C}_{16}\text{H}_{27}\text{O}_3$  PS  $[\text{M}]^+$  330.1419 found: 330.1422.

### *O,O*-Diisobutyl *S*-(2-methylbenzyl) phosphorothioate (**3q**)



The title compound was prepared following the general procedure for table 2, using 2-(4-methoxyphenyl)-4,6-di-*o*-tolyl-1,3,5,2-trithiaphosphinane 2-sulfide (**1c**) (284.7 mg, 0.6 mmol), di-isobutyl phosphite (**2b**) (77.68 mg, 0.4 mmol),  $\text{Cs}_2\text{CO}_3$  (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography ( $\text{SiO}_2$ , ethyl acetate/hexane) to provide **3q** (79.30 mg, 60% yield);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.32-7.30 (m, 1H), 7.20-7.12 (m, 3H), 4.06 (d,  $J = 12.0$  Hz, 2H), 3.85-3.80 (m, 2H), 3.75-3.70 (m, 2H), 2.40 (s, 3H), 1.97-1.87 (m, 2H), 0.93 (d,  $J = 1.2$  Hz, 6H), 0.91 (d,  $J = 1.2$  Hz, 6H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  136.6, 135.1 (d,  $J = 6.0$  Hz), 130.5, 129.9, 128.0, 126.2, 73.3 (d,  $J = 7.0$  Hz), 33.0 (d,  $J = 3.0$  Hz), 28.9 (d,  $J = 7.0$  Hz), 19.1, 18.6.  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  27.5. HRMS (EI) calcd for  $\text{C}_{16}\text{H}_{27}\text{O}_3\text{PS}$   $[\text{M}]^+$  330.1419 found: 330.1416.


### *O,O*-Diisobutyl *S*-(3-methoxybenzyl) phosphorothioate (**3r**)



The title compound was prepared following the general procedure for table 2, using 4,6-bis(3-methoxyphenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1e**) (304.0 mg, 0.6 mmol), di-isobutyl phosphite (**2b**) (77.68 mg, 0.4 mmol),  $\text{Cs}_2\text{CO}_3$  (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography ( $\text{SiO}_2$ , ethyl acetate/hexane) to provide **3r** (66.50 mg, 48% yield);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.23 (t,  $J = 8.0$  Hz, 1H), 6.95-6.91 (m, 2H), 6.80 (dd,  $J = 8.0$  & 2.0 Hz, 1H), 4.02 (d,  $J = 14.0$  Hz, 2H), 3.83-3.79 (m, 5H), 3.75-3.71 (m, 2H), 1.96-1.86 (m, 2H), 0.92 (d,  $J = 1.2$  Hz, 6H), 0.91 (d,  $J = 1.2$  Hz, 6H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  159.7, 138.9 (d,  $J = 6.0$  Hz), 129.7, 121.2, 114.3, 113.2, 73.3 (d,  $J = 6.0$  Hz), 55.2, 34.8 (d,  $J = 4.0$  Hz), 28.9 (d,  $J = 7.0$  Hz), 18.7.  $^{31}\text{P}$  NMR (162 MHz,


CDCl<sub>3</sub>):  $\delta$  27.4. HRMS (EI) calcd for C<sub>16</sub>H<sub>27</sub>O<sub>4</sub>PS [M]<sup>+</sup> 346.1368 found: 346.1363.

### ***O,O*-Diisobutyl *S*-(4-methoxybenzyl) phosphorothioate (**3s**)<sup>8</sup>**



The title compound was prepared following the general procedure for table 2, using 2,4,6-tris(4-methoxyphenyl)-1,3,5,2-trithiaphosphanane 2-sulfide (**1f**) (304.0 mg, 0.6 mmol), diisobutyl phosphite (**2b**) (77.68 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3s** (88.67 mg, 64% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.30-7.26 (m, 2H), 6.87-6.82 (m, 2H), 4.02 (d,  $J$  = 13.2 Hz, 2H), 3.84-3.78 (m, 5H), 3.74-3.68 (m, 2H), 1.96-1.87 (m, 3H), 0.93 (d,  $J$  = 3.0 Hz, 6H), 0.91 (d,  $J$  = 3.0 Hz, 6H); <sup>13</sup>C {H} NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  159.0, 130.1, 129.4 (d,  $J$  = 5.0 Hz), 114.4, 73.3 (d,  $J$  = 7.0 Hz), 55.3 (s), 34.5 (d,  $J$  = 4.0 Hz), 28.9 (d,  $J$  = 8.0 Hz), 18.6; <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  27.6. HRMS (EI) calcd for C<sub>16</sub>H<sub>27</sub>O<sub>4</sub>PS [M]<sup>+</sup> 346.1368 found: 346.1363.


### ***S*-(4-Fluorobenzyl) *O,O*-diisobutyl phosphorothioate (**3t**)**



The title compound was prepared following the general procedure for table 2 using 4,6-bis(4-fluorophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphanane 2-sulfide (**1g**) (289.4 mg, 0.6 mmol), diisobutyl phosphite (**2b**) (77.68 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3t** (77.57 mg, 58% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.36-7.32 (m, 2H), 7.03-6.98 (m, 2H), 4.03 (d,  $J$  = 14.0 Hz, 2H), 3.84-3.78 (m, 2H), 3.74-3.68 (m, 2H), 1.95-1.87 (m, 2H), 0.92 (d,  $J$  = 6.8 Hz, 12H); <sup>13</sup>C {H} NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  161.6 (d,  $J$  = 170.0 Hz), 133.2 (d,  $J$  = 125.0 Hz), 130.4 (d,  $J$  = 9.0 Hz), 115.6 (d,  $J$  = 21.0 Hz), 73.4 (d,  $J$  = 7.0 Hz), 34.2 (d,  $J$  = 4.0 Hz), 29.0 (d,  $J$  = 7.0 Hz), 18.7; <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>):  $\delta$  27.1; <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  -114.5. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>FO<sub>3</sub>PS [M]<sup>+</sup> 334.1168 found: 334.1172.


### ***S*-(4-Chlorobenzyl) *O,O*-diisobutyl phosphorothioate (**3u**)**






The title compound was prepared following the general procedure for table 2, using 4,6-bis(4-chlorophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1h**) (309.2 mg, 0.6 mmol), di-isobutyl phosphite (**2b**) (77.68 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3u** (70.16 mg, 50% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.32-7.27 (m, 4H), 4.01 (d, *J* = 14.4 Hz, 2H), 3.83-3.77 (m, 2H), 3.73-3.67 (m, 2H), 1.95-1.85 (m, 2H), 0.91 (d, *J* = 6.8 Hz, 12H); <sup>13</sup>C{H}NMR (100 MHz, CDCl<sub>3</sub>): δ 136.2 (d, *J* = 5.0 Hz), 133.4, 130.3, 128.8, 73.4 (d, *J* = 7.0 Hz), 34.2 (d, *J* = 4.0 Hz), 28.9 (d, *J* = 7.0 Hz), 18.6. <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 27.0. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>ClO<sub>3</sub>PS [M]<sup>+</sup> 350.0872 found: 350.0869.

### S-(3-Bromobenzyl) O,O-diisobutyl phosphorothioate (**3v**)




The title compound was prepared following the general procedure for table 2, using 4,6-bis(3-bromophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1i**) (362.6 mg, 0.6 mmol), di-isobutyl phosphite (**2b**) (77.68 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3v** (102.77 mg, 65% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.52 (t, *J* = 1.6 Hz, 1H), 7.40-7.37 (m, 1H), 7.31-7.27 (m, 1H), 7.19 (t, *J* = 8.0 Hz, 1H), 3.98 (d, *J* = 14.8 Hz, 2H), 3.84-3.79 (m, 2H), 3.74-3.67 (m, 2H), 1.95-1.85 (m, 2H), 0.92 (d, *J* = 0.8 Hz, 6H), 0.90 (d, *J* = 1.2 Hz, 6H); <sup>13</sup>C{H}NMR (100 MHz, CDCl<sub>3</sub>): δ 134.0 (d, *J* = 5.0 Hz), 125.8, 124.6, 124.1, 121.5, 116.4, 67.3 (d, *J* = 7.0 Hz), 28.1, 22.8 (d, *J* = 8.0 Hz), 12.6; <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 26.85. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>BrO<sub>3</sub>PS [M]<sup>+</sup> 394.0367 found: 394.0358.

### S-(4-bromobenzyl) O,O-diisobutyl phosphorothioate (**3w**)




The title compound was prepared following the general procedure for table 2, using 4,6-bis(4-bromophenyl)-2-(4-methoxyphenyl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1j**) (362.6 mg, 0.6 mmol), di-isobutyl phosphite (**2b**) (77.68 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3w** (109.10 mg, 69% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.46-7.43 (m, 2H), 7.26-7.23 (m, 2H), 3.99 (d, *J* = 14.8 Hz, 2H), 3.83-3.77 (m, 2H), 3.73-3.67 (m, 2H), 1.95-1.85 (m, 2H), 0.91 (d, *J* = 6.8 Hz, 12H). <sup>13</sup>C{<sup>1</sup>H}NMR (100 MHz, CDCl<sub>3</sub>): δ 136.7 (d, *J* = 5.0 Hz), 131.7, 130.6, 121.5, 73.4 (d, *J* = 6.0 Hz), 34.2 (d, *J* = 4.0 Hz), 28.8 (d, *J* = 8.0 Hz), 18.6. <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 26.9. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>BrO<sub>3</sub>PS [M]<sup>+</sup> 394.0367 found: 394.0364.

### ***S*-(4-Iodobenzyl) *O,O*-diisobutyl phosphorothioate (**3x**)**



The title compound was prepared following the general procedure for table 2, using 4-iodobenzothialdehyde **1k** (148.8 mg, 0.6 mmol), di-isobutyl phosphite **2b** (419.0 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3x** (72.53 mg, 41% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.64 (dt, *J* = 8.8 & 2.4 Hz, 2H), 7.12 (dt, *J* = 8.8 & 2.4 Hz, 2H), 3.98 (d, *J* = 14.8 Hz, 2H), 3.82-3.77 (m, 2H), 3.72-3.66 (m, 2H), 1.94-1.84 (m, 2H), 0.91 (d, *J* = 0.8 Hz, 6H), 0.90 (d, *J* = 0.8 Hz, 6H); <sup>13</sup>C{<sup>1</sup>H}NMR (100 MHz, CDCl<sub>3</sub>): δ 137.7, 137.5 (d, *J* = 5.0 Hz), 130.9, 93.0, 73.4 (d, *J* = 7.0 Hz), 34.4 (d, *J* = 4.0 Hz), 28.9 (d, *J* = 8.0 Hz), 18.7; <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>): δ 26.9. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>IO<sub>3</sub>PS [M]<sup>+</sup> 442.0228 found: 442.0234.


### ***O,O*-Diisobutyl *S*-(4-nitrobenzyl) phosphorothioate (**3y**)**



The title compound was prepared following the general procedure for table 2, using 4-nitrobenzothialdehyde **1n** (100.3 mg, 0.6 mmol), di-isobutyl phosphite **2b** (77.68 mg, 0.4 mmol), Cs<sub>2</sub>CO<sub>3</sub> (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography (SiO<sub>2</sub>, ethyl acetate/hexane) to provide **3y** (43.36 mg, 30% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.20-8.16 (m, 2H), 7.58-7.55 (m, 2H), 4.12 (d, *J* = 15.6 Hz, 2H), 3.84-


3.75 (m, 2H), 3.74-3.68 (m, 2H), 1.95-1.85 (m, 2H), 0.85 (d,  $J = 6.9$  Hz, 12H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  147.2, 145.4 (d,  $J = 4.0$  Hz), 129.7, 123.8, 73.6 (d,  $J = 7.0$  Hz), 34.0 (d,  $J = 4.0$  Hz), 29.8 (d,  $J = 7.0$  Hz), 18.6;  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  26.2. HRMS (EI) calcd for  $\text{C}_{15}\text{H}_{24}\text{NO}_5\text{PS}$   $[\text{M}]^+$  361.1113 found: 361.1117.

### ***O,O*-diisobutyl *S*-(naphthalen-2-ylmethyl) phosphorothioate (**3z**)**



The title compound was prepared following the general procedure for table 2, using 2-(4-methoxyphenyl)-4,6-di(naphthalen-2-yl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1l**) (328.0 mg, 0.6 mmol), di-isobutyl phosphite (**2b**) (77.68 mg, 0.4 mmol),  $\text{Cs}_2\text{CO}_3$  (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography ( $\text{SiO}_2$ , ethyl acetate/hexane) to provide **3z** (89.41 mg, 61% yield);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.07 (d,  $J = 8.4$  Hz, 1H), 7.83 (d,  $J = 8.0$  Hz, 1H), 7.76 (d,  $J = 8.0$  Hz, 1H), 7.57-7.47 (m, 3H), 7.39-7.35 (m, 1H), 4.51 (d,  $J = 12.4$  Hz, 2H), 3.83-3.76 (m, 2H), 3.73-3.67 (m, 2H), 1.92-1.82 (m, 2H), 0.89 (d,  $J = 4.0$  Hz, 6H), 0.87 (d,  $J = 4.0$  Hz, 6H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  133.7, 132.6 (d,  $J = 6.0$  Hz), 130.9, 128.77, 128.70, 127.6, 126.3, 125.8, 125.2, 123.5, 73.2 (d,  $J = 7.0$  Hz), 32.6 (d,  $J = 4.0$  Hz), 28.7 (d,  $J = 7.0$  Hz), 18.5;  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ )  $\delta$  27.4. HRMS (EI) calcd for  $\text{C}_{19}\text{H}_{27}\text{O}_3\text{PS}$   $[\text{M}]^+$  366.1419 found: 366.1416.

### ***O,O*-diisobutyl *S*-(thiophen-2-ylmethyl) phosphorothioate (**3aa**)**







The title compound was prepared following the general procedure for table 2, using 2-(4-methoxyphenyl)-4,6-di(thiophen-2-yl)-1,3,5,2-trithiaphosphinane 2-sulfide (**1m**) (275.1 mg, 0.6 mmol), di-isobutyl phosphite (**2b**) (77.68 mg, 0.4 mmol),  $\text{Cs}_2\text{CO}_3$  (52.13 mg, 40 mol%) and EA (2.0 mL), then purified by column chromatography ( $\text{SiO}_2$ , ethyl acetate/hexane) to provide **3aa** (54.16 mg, 42% yield);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.22 (dd,  $J = 5.2$  & 1.2 Hz, 1H), 7.03 (dd,  $J = 3.6$  & 1.2 Hz, 1H), 6.91 (dd,  $J = 5.2$  & 3.6 Hz, 1H), 4.28 (d,  $J = 13.6$  Hz, 2H), 3.88-3.82 (m, 2H), 3.78-3.72 (m, 2H), 1.99-1.88 (m, 2H), 0.93 (d,  $J = 17.0$  Hz, 12H);  $^{13}\text{C}\{\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  140.0 (d,  $J = 6.0$  Hz), 127.1, 126.8, 125.6, 73.3 (d,  $J = 7.0$



Hz), 29.4 (d,  $J = 3.0$  Hz), 28.9 (d,  $J = 8.0$  Hz), 18.6;  $^{31}\text{P}$  NMR (162 MHz,  $\text{CDCl}_3$ ):  $\delta$  26.7. HRMS (EI) calcd for  $\text{C}_{13}\text{H}_{23}\text{O}_3\text{PS}_2$   $[\text{M}]^+$  322.0826 found: 322.0819.



#### 4. References

1. Chen, Y.; Li, M.; Goug, Z.; Shen, Z.; *Phosphorus Sulfur Silicon Relat Elem.* **2021**, *196*, 19.
2. Mondal, M.; Saha, A. *Tetrahedron Letters.* **2019**, *60*, 150965.
3. Kaboudin, B.; Farjadian, F. *Beilstein. J. Org. Chem.* **2006**, *2*, 4.
4. Xue, J.-W.; Zeng, M.; Zhang, S.; Chen, Z.; Yin, G. *J. Org. Chem.* **2019**, *84*, 4179
5. Min, C.; Zhang, R.; Liu, Q.; Lin, S. *Synlett*, **2018**, *29*, 2027.
6. Pluempanupat, W.; Temyarasilp, P.; Widhalm, M.; Chavasiri, W. *J. Sulfur Chem.*, **2014**, *35*, 418.
7. Han, X.; Wu, J. *Org Lett.*, **2010**, *12*, 5780.
8. Ghantwal, S. R.; Samant, S. D. *Chem. Abstr.*, **1968**, *69*, 2627.

























(<sup>13</sup>C{H} NMR, CDCl<sub>3</sub>, 100 MHz)







(<sup>31</sup>P NMR, CDCl<sub>3</sub>, 162 MHz)

































































—7287

<sup>31</sup>P NMR, CDCl<sub>3</sub>, 162 MHz

$^1\text{H}$ ,  $^{13}\text{C}$ ,  $^{31}\text{P}$  &  $^{19}\text{F}$  NMR spectra of compounds 3



—27.36

<sup>31</sup>P NMR, CDCl<sub>3</sub>, 162 MHz7.270  
7.239  
7.210  
7.192  
7.163  
7.153  
7.098  
7.0704.181  
4.161  
4.162  
4.154  
4.144  
4.141  
4.138  
4.128  
4.125  
4.110  
4.098  
4.086  
4.081  
4.068  
4.051  
4.046  
4.038  
4.028  
4.024  
3.980

—2.341



1.316  
1.288  
1.281

—0.000

<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz







$^{13}\text{C}\{\text{H}\}$  NMR,  $\text{CDCl}_3$ , 100 MHz




-27.46


$^{31}\text{P}$  NMR,  $\text{CDCl}_3$ , 162 MHz







(<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz)



137.32  
134.31  
134.25  
129.26  
128.73


77.42  
77.10  
76.78

63.47  
63.42

34.71  
34.67



21.05  
15.93  
15.86

(<sup>13</sup>C{H} NMR, CDCl<sub>3</sub>, 100 MHz)







27.55



(<sup>31</sup>P NMR, CDCl<sub>3</sub>, 162 MHz)





















— 27.09

<sup>31</sup>P NMR, CDCl<sub>3</sub>, 162 MHz



— 114.58

<sup>19</sup>F NMR, CDCl<sub>3</sub>, 376 MHz



—26.95

(<sup>31</sup>P NMR, CDCl<sub>3</sub>, 162 MHz)





7.524  
7.411  
7.381  
7.366  
7.248  
7.212  
7.193  
7.173

4.173  
4.168  
4.148  
4.137  
4.135  
4.130  
4.117  
4.112  
4.110  
4.099  
4.092  
4.071  
4.063  
4.059  
4.045  
4.041  
4.027  
4.023  
4.021  
4.016  
4.004  
3.986  
3.966

1.314  
1.297



—0.000

(<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz)







(<sup>13</sup>C{H} NMR, CDCl<sub>3</sub>, 100 MHz)







36.79

(<sup>31</sup>P NMR, CDCl<sub>3</sub>, 162 MHz)













137.62  
137.31  
137.26  
130.78  
99.00  
77.42  
77.10  
76.78  
69.60  
69.54  
34.32  
34.28  
15.92  
15.84



(<sup>13</sup>C{H} NMR, CDCl<sub>3</sub>, 100 MHz)





26.89

(<sup>31</sup>P NMR, CDCl<sub>3</sub>, 162 MHz)







140.15  
140.09

127.15  
126.90  
125.72


77.43  
77.10  
76.78

63.70  
63.65

29.57  
29.54


16.01  
15.94



(<sup>13</sup>C{H} NMR, CDCl<sub>3</sub>, 100 MHz)





26.69

(<sup>31</sup>P NMR, CDCl<sub>3</sub>, 162 MHz)

















( $^{13}\text{C}\{\text{H}\}$  NMR,  $\text{CDCl}_3$ , 100 MHz)






27.58



( $^{31}\text{P}$  NMR,  $\text{CDCl}_3$ , 162 MHz)











-27.40



 $(^{31}\text{P NMR, CDCl}_3, 162 \text{ MHz})$  $(^1\text{H NMR, CDCl}_3, 400 \text{ MHz})$ 




















—37.14



 $^{31}\text{P}$  NMR,  $\text{CDCl}_3$ , 162 MHz**3t**



—114.51


 $^{19}\text{F}$  NMR,  $\text{CDCl}_3$ , 376 MHz**3t**












7.664, 7.658, 7.653, 7.642, 7.637, 7.631, 7.267, 7.138, 7.132, 7.127, 7.116, 7.111, 7.105, 3.995, 3.958, 3.823, 3.807, 3.799, 3.782, 3.766, 3.721, 3.704, 3.656, 3.621, 3.662, 1.943, 1.926, 1.909, 1.892, 1.876, 1.859, 1.843, 0.921, 0.919, 0.904, 0.902, -0.000



2.00, 2.03, 2.10, 2.13, 2.11, 2.05, 6.15, 6.22

137.79  
137.55  
137.50  
130.97



98.13

77.41  
77.10  
76.78  
76.52  
76.46

34.42  
34.38  
29.01  
28.98


18.74



(<sup>13</sup>C{H} NMR, CDCl<sub>3</sub>, 100 MHz)



26.96




(<sup>31</sup>P NMR, CDCl<sub>3</sub>, 162 MHz)











— 36.29

<sup>31</sup>P NMR, CDCl<sub>3</sub>, 162 MHz<sup>1</sup>H NMR, CDCl<sub>3</sub>, 400 MHz





—36.72

<sup>31</sup>P NMR, CDCl<sub>3</sub>, 162 MHz